Alvircept sudotox

DRUG2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Pharmacia and Upjohn

Conditions

HIV Infections

Phase 1

A Phase I, Dose-Escalating Safety and Tolerance Study of sCD4-PE40 in HIV-Infected Persons

CompletedNCT00000743

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

End: 1995-05-31Target: 64Updated: 2021-10-28

Safety, Tolerance, Efficacy and Pharmacokinetics of Multiple Doses of sCD4-PE40 in the Treatment of HIV-Infected Individuals

CompletedNCT00002087

Pharmacia and UpjohnHIV Infections

Updated: 2005-06-24